Kiniksa Pharmaceuticals (KNSA) 10-Q2023 Q1 Quarterly report

Filed: 4 May 23, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: accretion, Albumin, Amgen, analytical, arbitration, auxiliary, Bill, bioequivalence, certificate, comprised, confirmatory, danger, decree, default, DEI, depict, depleted, devastation, entrance, ESG, expressly, felt, forward, Halia, hit, inflammasome, intracellular, Iowa, kidney, LLC, ministerial, NodThera, OECD, Olatec, Onzomelid, organizational, pharmacokinetic, Portability, practitioner, ratification, repaired, revisit, Selnoflast, sensor, sentiment, Somalix, Summary, supplementary, synergistic, task, TCA, therefrom, unified, variant, Ventyx, workforce

Removed: Abbvie, abrupt, Absent, accommodation, altogether, American, antikickback, assessed, assume, back, backlog, bilateral, bleselumab, Boehringer, cardiology, cleaning, Commissioner, complicated, complied, compounded, conditioned, contact, destination, distancing, diverge, diverting, dose, downturn, driver, easing, enabling, enhanced, escalate, exploitation, explore, extreme, faced, flexibility, functional, gevokizumab, GILTI, GlaxoSmithKline, graft, GSK, harder, immunological, impeded, inclusion, Ingelheim, inpatient, interacting, interrupting, introducing, JSC, loosened, loosening, losing, measure, measuring, medium, migrated, minimize, model, Omicron, oncologic, onset, organ, otilimab, outlined, parallel, passage, pause, perception, persistent, Pharma, posing, positioned, postmarketing, predominant, preparing, principle, prompting, protective, provisionally, pursuit, ratified, ravagalimab, recognizing, reevaluate, referendum, reflective, refusal, reinstated, repealed, represented, reprioritization, reprioritizing, Rescue, retention, route, scale, serving, solid, sourcing, spread, SSP, Steering, subcutaneously, sustainability, sustaining, tracing, transitional, transplant, transport, traveling, unconditional, undertaken, vaccinated, varied, visiting, wake, widespread, withdrew

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated KNSA transcripts

KNSA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Directors of Kiniksa Pharmaceuticals, Ltd. (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


May 4, 2023	/s/ Sanj K. Patel
	Sanj K. Patel
	Chief Executive Officer and Chairman of the Board of Directors
	(Principal Executive Officer)